A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma.
Damato AR, Katumba RGN, Luo J, Atluri H, Talcott GR, Govindan A, Slat EA, Weilbaecher KN, Tao Y, Huang J, Butt OH, Ansstas G, Johanns TM, Chheda MG, Herzog ED, Rubin JB, Campian JL.
Damato AR, et al.
Neurooncol Pract. 2022 Jan 31;9(3):193-200. doi: 10.1093/nop/npac003. eCollection 2022 May.
Neurooncol Pract. 2022.
PMID: 35601970
Free PMC article.